Trial · NCT05214794
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 | Baseline and week 24 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24 | From baseline up to Week 24 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24 | From baseline up to Week 24 | FAS population included all participants who were enrolled. | percentage of actual to predicted FCV | MEDIAN |
| SECONDARY | Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | percentage of actual to predicted FCV | MEDIAN |
| SECONDARY | Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24 | From baseline up to Week 24 | FAS population included all participants who were enrolled. | percentage of actual to predicted DLco | MEDIAN |
| SECONDARY | Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | percentage of actual to predicted DLco | MEDIAN |
| SECONDARY | Change From Baseline in Physician's Global Assessment at Week 24 | From baseline up to Week 24 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Physician's Global Assessment at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Patient's Global Assessment at Week 24 | From baseline up to Week 24 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
| SECONDARY | Change From Baseline in Patient's Global Assessment at Week 52 | From baseline up to Week 52 | FAS population included all participants who were enrolled. | scores on scale | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05214794/outcomes